Supplementary Figure 3: DH-CBD does not significantly alter strychnine inhibition of GlyRs.
From: Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia disease
(a). Gly concentration-response curves in the absence and presence of strychnine in HEK-293 cells expressing α1GlyRs. Strychnine at 0.1 μM produced in parallel a right shift of Gly concentration-response curve, respectively. The EC50 values are 56±8 μM for vehicle control (black squares, n=9) and 366±74 μM for strychnine treatment (blue squares, n=7). These values are significantly different (unpaired test, p=0.0023). ; DH-CBD did not significantly alter strychnine inhibition of the agonist binding affinity of α1GlyRs (red squares, n=7, Gly EC50: 368±84 μM. strychnine VS strychnine+DH-CBD , p=0.92) (b) Strychnine (n=6, 1 mg/kg, i.p.) produced exaggerated startle response to acoustic stimulation in C57/BL6 mice (p=0.006, two-way ANOVA). Preadministration of DH-CBD (n=6, 50 mg/kg, i.p.) did not reverse strychnine-induced exaggerated acoustic startle response (p=0.88, two-way ANOVA).
